Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas

E. Gaudio, C. Tarantelli, I. Kwee, C. Barassi, E. Bernasconi, A. Rinaldi, M. Ponzoni, L. Cascione, A. Targa, A. Stathis, S. Goodstal, E. Zucca, F. Bertoni

Research output: Contribution to journalArticle

Fingerprint Dive into the research topics of 'Combination of the MEK inhibitor pimasertib with BTK or PI3K-delta inhibitors is active in preclinical models of aggressive lymphomas'. Together they form a unique fingerprint.

Medicine & Life Sciences